Main Web Site : www.henderson-morley.com

On line shop web site : http://www.herpesexpert.com (Frost and Simpson)

Investor Relations email : investors@henderson-morley.com

Henderson Morley is a drug discovery company

The company has been developed specifically to carry out preliminary sourcing and screening of candidates to combat diseases caused by the herpes family of viruses and certain other DNA viruses

Latest GECR update 15th October 2006

Latest GE&CR update - 15th Oct 2006 :


The news investors have all been waiting for - regarding negotiations with a US dermatological pharmaceutical firm has finally been unveiled. The licence has been granted under an agreement to
Cutanea, a U.S. pharmaceutical company, specialising in the development of dermatology products in the US market.

The licence is for new applications of ICVT for the treatment of dermatological conditions in humans. The agreement and takes the form of an exclusive American, Mexican and Canadian wide licence to bring products to market through a programme of pre-clinical and clinical development of treatments either by Cutanea or through a sub-licence. Under the terms of the Agreement, Henderson Morley will receive up to 6.675 million dollars in development and commercialisation milestone payments up to the point at which the application receives regulatory approval, and will receive royalties on net sales thereafter.

Under its business plan, Henderson Morley has stated its belief that, following clinical development and regulatory licence approval, sales of the product in excess of $1.5 billion could be achieved over the subsequent ten year period. This would give a potential royalty to Henderson Morley in excess of $115 million over this term.

As a drug discovery company, it is imperative that Henderson continues to grant licenses to further develop its technology portfolio. This is the group's third ICVT license agreement. Encouragingly, Cutanea has a great management team with a proven track record of commercialising dermatology products.

Meanwhile, the company has announced that it has been working away on a vaccine against Koi Carp Herpes virus. The group believes it is now ready to start field trials of a
candidate vaccine, in a collaboration with the Internationally renowned Hagerman
Aquaculture Research Institute in Idaho USA. The initial immunogenicity studies should produce results within 6 months, enabling Henderson Morley scientists to optimise the vaccine formulation, with a view to securing a product licence from the veterinary authorities as soon as practicable.

Clearly activity at Henderson Morley has been significant in recent weeks. The licensing announcement is very encouraging, but with the news now out of the way, the shares have eased - a classic case of buy on the rumour, sell on the news. That said, the stock has now pulled back below the recent placing price. With so much going on at the company, further newsflow in the shorter term is far from unlikely.

*Henderson Morley is a corporate client of Bishopsgate Communications which is owned by RSH, the ultimate owner of GE&CR.

Forecasts and a formal recommendation are suspended ahead of the publication of a detailed note next month.

LOL have a look at ecpc they have made a mistake RNS is giving .95 on the 29th whilst the share price is only .2

Oilivergas, khv' s on its way by the sounds of todays rns.

I don't like a strategic Review hanging about (since July07!), to make up their mind what to do. . . . Looks a bit like Eyes-off-ball . . . . meanwhile the sp drifts down.
Hardly a "speculative Buy" ( Thread subject). . . . ''loss'' is more like it.
This co has always been poor on information and the sp drift tells it all. I have a small holding now, from higher - but then so does everyone.

Sheering-Plough deal looks OK, but [HML[ needed to raise further capital at 0.6pence, so the sp has a new-low to reach.
The Sheering-Plough deal is for Koi-Carp treatment over three-years....so a thin coating of Jam (3-years hence).
-Obviously good news if you're a Koi-carp with a rather nasty infection . . . . . and can wait 3-years.
.....Oh dear......
EDIT..May08 ...Looks like the Company is attempting to keep investors informed, as regards future programmes, income and other "forward-looking" possibilities. Whilst this is not yet "income" it may at least align Company Bosses with expectations.... (ends)

It looks like HML are on the way out. They are at an historic low and their short / medium term prospects look bleak.

Henderson Morley PLC

(the 'Company')


Directors' Shareholding


The Company received the following notification on July 22 confirming transactions in the Company's share capital by a director of the Company.

Mr A Knight, Chairman, has today purchased the following shares at the following prices:


Number Price


100,000 0.55p

350,000 0.60p

225,000 0.65p

As a result Mr Knight has an interest in 85,653,764 shares in the Company, representing 14.89 per cent. of the issued share capital of the Company.

RNS Number : 8494Z
Henderson Morley PLC
25 July 2008

25 July 2008

Henderson Morley PLC

(the 'Company')

Directors' Shareholding

The Company received the following notification on July 24 confirming transactions in the Company's share capital by a director of the Company.

Mr A Knight, Chairman, has today purchased the following shares at the following prices:
Number Price

500,000 0.60p

As a result Mr Knight has an interest in 86,153,764 shares in the Company, representing 14.97 per cent. of the issued share capital of the Company
--ENDS--

He is picking up shed loads on the cheap. Either he is worried at the sp fall or, more likely, he knows that he is going to make a packet when they finally move up.

yes,could be either but I take it as a positive sign until proven otherwise.

There must be some news out there or about to break......

Well it's not the Director Buy - just 3k's worth, less than he'd pay for a daughter's car. I do not consider a DIR purchase significant unless it's 50k+ and this is telling me quite the opposite.....better to have bought nothing...Oh deary.

For the MM's to raise the sp 30% must think we're MUGS. Following the Rules - AK will not know of any price-sensitive information - so this purchase tells us "There Is No News"

Now watch that sp fall.

Pity their treatment can't transform Koi into mermaids...or turn a dire stock into - - - . I hold from about 3p...ouch.

hangon,you sound very bitter!

I'm nearly at break even so very happy and looking forward to the future.

hangon,sorry I was a bit short with yer earlier but your post didn't make sense-lol

"Following the Rules -AK will not know of any price-sensitive information - so this purchase tells us "There Is No News""- I'm sure the Chairman knows what's going on within the company and this is the AIM after all! :-)

There may or may not be news next week but the SP held up pretty well after quite a rise.

It's his total interest in HML that counts:

"Mr Knight has an interest in 86,153,764 shares in the Company, representing 14.97 per cent."

Interesting couple of weeks for HML methinks! Is there news waiting to be announced,AK just topping up as he knows the company has or is close to making a major deal,AK just trying to add confidence with his buys and no news in pipeline or.................could go on-lol.

A lot of upside if there is positive news but will have to wait and see with this one.

Are we seeing the start of something here? Will have to be news driven to continue..........obv.

Nice little rise and the above post still applies.
:-)

RNS Number : 9870J
Nice little rise today,I see.


Henderson Morley PLC
11 December 2008

11 December 2008



HENDERSON MORLEY PLC

(AIM: HML)



('Henderson Morley' or 'the Company')



HYBRIDAN INITATES COVERAGE ON HENDERSON MORLEY



The Board of Henderson Morley plc, the AIM quoted biotechnology company, is pleased to announce that Hybridan, the Company's house broker, has today initiated coverage on the Company. To view the research note please visit http://www.henderson-morley.com/news.php



Hybridan has given Henderson Morley a buy recommendation and a target price of 4.72p. This is based on the significant revenue potential of the Company's technology platforms.



Highlights



Hybridan believes that the Company's value is mainly tied to the intellectual property related to its three technologies, which provide a competitive advantage due to their unique mechanism of action and their impressive efficacy and safety profile.


The Company has three business divisions: Pharmaceuticals (based on ICVT), Animal Health (based on ICVT and its proprietary technology PREPS and L-particles), and Vaccines (also based on PREPS and L-particles).

Given the impressive revenue potential and low costs of development and production of its programmes, Hybridan believes that Henderson Morley has the potential to out license its candidates and sign deals with up front-, ongoing milestone- and royalty payments.


Using a probability-adjusted Sum of the Parts (SOTP) DCF model, Hybridan estimates Henderson Morley's fair value at 4.72 pence per share, with ICVT, Animal Health and Vaccines contributing 29%, 68% and 4%, respectively.


Hybridan believes a number of indications are not included in its valuation and Henderson Morley's progression in these would provide an obvious upside.



---ENDS---

http://moneyam.uk-wire.com/cgi-bin/articles/200812111515079870J.html

23 December 2008


HENDERSON MORLEY PLC

(AIM: HML)

Koi Vaccine Update

The Board of Henderson Morley announces that further to the Chairman's statement which accompanied the results for the full year, the initial phase of the field studies has now been completed.

The vaccine candidates under examination were formulated to give a wide range of doses, using proprietary adjuvants (compounds that help boost and increase the duration of immune responses). The results from the study have demonstrated that the vaccine candidates were safe and well tolerated, with adverse effects no greater than unvaccinated controls.

Fish were vaccinated and examined, amongst other parameters, for immune responses to vaccination, vaccination dose, vaccination safety and assessment of the safety and immunogenicity of the new adjuvant. The studies have given a much greater understanding of immune responses and dose requirements. It is likely that from the next phase of studies, due to start in Jan 2009, a final vaccine candidate will be selected.

Commenting on the announcement, Andrew Knight, Henderson Morley Executive Chairman said: 'This is an important first stage in studying the efficacy of the KHV vaccine. We can now move forwards to the next phase of the study which we anticipate will start in early January 2009.'

http://moneyam.uk-wire.com/cgi-bin/articles/200812230700106408K.html

A little bit of movement here too!

Hmmmmmm........

14January 2009


HENDERSON MORLEY PLC
(AIM: HML)
('HendersonMorley' or 'the Company')

DOG CANCERCOLLABORATION

Henderson Morley ispleased to announce the start of a Collaborative Research Programme withaUSbased centre of excellence for companion animal cancer. The centre is the largest research unit for animalcancers intheUS, and the collaborationisto develop treatmentsfor twodifferent forms of dog cancer.

For the first time, the studies will exploretheuseof PREPS and L-particlesas a treatment for cancer. The studywill involve dogsthatalreadyhavecancer, andtheir existing treatment has either failed or is likely to prove ineffective.

PREPS and L-particles have beenengineered to express proteins that are only found in tumours, or are over produced by certaincancers.Inaffected animals, these proteins are not recognised by the immune system as beingforeign, and therefore thetumours areable to grow.PREPS and L-particles present these engineered proteins to the immune systemsothat animmune response is expected to be generated against them,mobilising the animals'immune system against the tumours.

The market fordog cancertreatmentsis significant and growing, as dogs are living longer, and pet ownership is increasing. There are 74 million dogs owned in theUS, with 4 million new dog cancer diagnoses being made every year.We believe that the numbers in the EU are similar.Thefirsttwo cancers under investigation are two of the most common forms of dog cancerwith a large potential market.

The data generated in these studies will also be extremely useful in support of the on-going licensing efforts for the use of PREPS and L-particles as treatments for human cancer.

Ethics committee approval for the first of these two studies has been granted, and the second is expected to be approved withina fewweeks.It is expected tostart recruitingpatients in March-Aprilwith approximately 10 animals involved in each study.The time taken to gain marketing approval for companion animal cancer products is significantly shorter than the human equivalent.

The Company isalreadyindiscussionswith major animal health companies to seekdevelopmentagreementsoran out-licenceof thecompanioncancerapplications of PREPS and L-particles.

Executive ChairmanAndrew Knightsaid'This is an important potential commercial application for thePREPS and L-particles vaccine platformand we are pleased to be working with the Centre of Excellence in this respect. The companion animal market is clearly a growing opportunity forHendersonMorley.'

---ENDS--